drugset / Trial / NCT05790499

LDL-c Level Variability and Trained Immunity

NCT05790499

NaSingle-groupOpen-labelTreatment

Summary

Statin treatment significantly reduces the incidence of cardiovascular events. However, cholesterol variability is associated with the risk of adverse events such as mortality, myocardial infarction, and stroke. The previous research found that the inflammatory activity of peripheral blood mononuclear cells in mice fed with intermittent high-fat diet was significantly increased, and the cholesterol variability had an impact on the trained immunity of peripheral blood mononuclear cells, thus aggravating the atherosclerosis in mice. We plan to compare the differences in serum LDL-C levels after intermittent atorvastatin treatment and continuous atorvastatin treatment, and investigate the impact of this difference on the trained immunity of peripheral blood mononuclear cells.

Timeline

Start
2023-03-20
Primary completion
2023-12-31
Completion
2024-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 40 mg